••
Florida Blue
Florida Blue has implemented a comprehensive management program, following guidance from the Centers
for Disease Control and Prevention, to address opioid use disorder in Florida. Focusing on safety first,
known opioid best management practices were implemented which includes providing a host of services for
providers and members. The company’s programs include the use of physician/member treatment
agreements, analytics to identify “doctor shopping” and narcotic diversion, along with limiting day supply and
ensuring appropriate utilization and dosing through medical coverage policies. In addition, Florida Blue
requires both providers and pharmacies to utilize the state’s Prescription Drug Monitoring Program (PDMP)
before writing and dispensing opioid prescriptions. The company retrospectively reviews controlled
substance claims, consults with prescribers and members by phone about narcotic use, refers members to
pain and/or behavioral health specialists when appropriate, conducts regular pharmacy audits, provides
prescribers with education and limits members to one prescriber and one pharmacy or pharmacy chain when
appropriate. Florida Blue’s program has yielded a reduction in controlled substance claims, and providers
have reacted positively.
Health Care Service Corporation (HCSC)
HCSC, which operates Blue Cross and Blue Shield companies in Illinois, Montana, New Mexico, Oklahoma
and Texas, applies a multi-pronged approach to manage controlled substances. HCSC’s Controlled Drug
Substance (CDS) program identifies opportunities to help improve member care by monitoring pharmacy
claims data for the potential misuse of controlled substances. An informational letter is sent to the prescriber
to help reassess the member’s treatment regimen. The company’s comprehensive Controlled Substance
Integration (CSI) program is designed to identify patterns of atypical controlled substance usage and
intervene in cases of suspected misuse, abuse, opportunities for care coordination, patient or provider
management and/or education. The CSI Provider-Centric program reviews opioid prescribing patterns
among certain prescribers and engages them in opportunities and provides resources to support their
management of HCSC members.
HCSC also engages in collaborative efforts to manage fraud, waste and abuse (FWA). The Special
Investigations Department (SID) provides fraud detection, investigation and prevention services that can
include law enforcement and the pharmacy audit division. Comprehensive pharmacy audit and education
programs further promote these collaborative FWA efforts. Utilization management and drug utilization
review activities also allow for monitoring of potential drug therapy problems before dispensing.
Highmark, Inc.
Highmark Inc., which operates Blue Cross Blue Shield companies in Pennsylvania, West Virginia and
Delaware, has taken a number of strategic measures to address the opioid epidemic. Highmark is working
with providers to give them the resources and tools that support appropriate prescribing protocols. The
quality improvement program uses claims data to help physicians better understand their patients’ total
prescription and medication use and gain insight into their own prescribing patterns. Another program aims
to detect patients who might be addicted to opioid pain pills by limiting them to using only one pharmacy
when filling prescriptions for controlled substances
. Other initiatives includ
e the addition of pharm
acists to its
care management team to help members who have multiple health issues manage their prescription
medications safely and effectively and a $75,000 contribution to provide naloxone to local law enforcement
officials across Pennsylvania to fight the opioid overdose epidemic. Additionally, the Highmark Foundation
7